An ambitious new international collaboration, bolstered by a prestigious pan-European EUREKA grant, is set to revolutionize the treatment landscape for…
Read More
Terray’s TerraBind Delivers 26x Faster Inference and Enhanced Accuracy, Challenging Diffusion-Based AI Models in Drug Discovery
In a significant development poised to reshape the landscape of AI-driven drug discovery, Terray Therapeutics, a Los Angeles-based startup, has…
Read More
How Digital Tools and AI Are Accelerating Drug Discovery
The landscape of pharmaceutical innovation has long been characterized by arduous timelines, exorbitant costs, and a high probability of failure,…
Read More
FDA Rejects Moderna’s mRNA Flu Vaccine Application, Citing Comparator Study Flaws Amidst Broader Policy Shifts
Moderna, a leading biotechnology company, announced on Tuesday that the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation…
Read More
Closing the Information Gap: ETH Zurich Team Integrates Function and Binding in One Drug Screening Assay
A pioneering team of researchers from ETH Zurich and Karolinska Institutet has unveiled a groundbreaking cross-linking MALDI mass spectrometry (MS)…
Read More
SLAS 2026: Orchestration Platforms, API-First Instruments, and the Ascent of Semi-Autonomous Laboratories
The annual SLAS (Society for Laboratory Automation and Screening) conference, held in Boston from February 7th to 11th, 2026, typically…
Read More
Can live cell dynamics fix drug discovery’s efficacy problem?
The pharmaceutical industry, perpetually navigating a landscape of escalating costs and protracted timelines, faces a critical juncture where innovation is…
Read More
Novo Nordisk sues Hims for GLP-1 patent infringement
The pharmaceutical giant Novo Nordisk has initiated legal proceedings against Hims & Hers Health, Inc., alleging patent infringement related to…
Read More
From list price to net price: How finance leaders decode real drug costs
In the complex landscape of the healthcare industry, public discourse surrounding drug pricing frequently begins and ends with the list…
Read More
First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
For decades, successive waves of antidepressants have promised relief to millions suffering from mood disorders, yet the landscape for those…
Read More
